Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to -$44.4 million.

  • Lifecore Biomedical's Net Income towards Common Stockholders rose 71.10% to -$2.0 million in Q2 2025 from the same period last year, while for May 2025 it was -$44.4 million, marking a year-over-year decrease of 12610.32%. This contributed to the annual value of -$44.4 million for FY2025, which is 469.26% down from last year.
  • As of FY2025, Lifecore Biomedical's Net Income towards Common Stockholders stood at -$44.4 million, which was down 469.26% from $12.0 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Net Income towards Common Stockholders registered a high of $12.0 million during FY2024, and its lowest value of -$101.9 million during FY2022.
  • Over the past 3 years, Lifecore Biomedical's median Net Income towards Common Stockholders value was -$35.3 million (recorded in 2023), while the average stood at -$22.6 million.
  • In the last 5 years, Lifecore Biomedical's Net Income towards Common Stockholders tumbled by 890.66% in 2022 and then surged by 134.01% in 2024.
  • MRY analysis of 5 years shows Lifecore Biomedical's Net Income towards Common Stockholders stood at -$10.3 million in 2021, then crashed by 890.66% to -$101.9 million in 2022, then skyrocketed by 65.34% to -$35.3 million in 2023, then skyrocketed by 134.01% to $12.0 million in 2024, then crashed by 469.26% to -$44.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$44.4 million for FY2025, versus $12.0 million for FY2024 and -$35.3 million for FY2023.